Dobutamine Potentiates the Peripheral Chemoreflex in Patients With Congestive Heart Failure

Sonia Velez-Roa, Philippe Van De Borne, Virend Somers

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: β-Adrenergic agonists may increase chemoreflex sensitivity to hypoxia in normal humans. Chemoreflex function is important in the pathophysiology of heart failure. Whether the β-1 agonist dobutamine, which is frequently administered to patients with heart failure, alters their chemoreflex sensitivity is not known. Methods: We tested the hypothesis that dobutamine increases chemoreflex sensitivity in patients with congestive heart failure (CHF) using a randomized, double-blinded, placebo-controlled study design. We assessed the influence of dobutamine on minute ventilation and hemodynamics during normoxic breathing and during peripheral chemoreflex deactivation by hyperoxia (100% O2) in 9 patients with CHF. Results: Dobutamine increased minute ventilation in patients with CHF (9.4 ± 0.9 versus 8.4 ± 0.7 L/min, P = .005) during normoxia. Peripheral chemoreflex deactivation by hyperoxia suppressed the ventilatory effects of dobutamine (10.4 ± 1.4 L/min for dobutamine versus 10.0 ± 1.2 L/min for placebo, P = .34). Conclusions: Dobutamine increases ventilation during normoxia, but not during hyperoxia in patients with CHF. We conclude that dobutamine enhances peripheral chemoreflex sensitivity in patients with congestive heart failure.

Original languageEnglish (US)
Pages (from-to)380-383
Number of pages4
JournalJournal of Cardiac Failure
Volume9
Issue number5
DOIs
StatePublished - Oct 2003

Fingerprint

Dobutamine
Heart Failure
Hyperoxia
Ventilation
Placebos
Adrenergic Agonists
Respiration
Hemodynamics

Keywords

  • Chemoreflex sensitivity
  • Congestive heart failure
  • Dobutamine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dobutamine Potentiates the Peripheral Chemoreflex in Patients With Congestive Heart Failure. / Velez-Roa, Sonia; De Borne, Philippe Van; Somers, Virend.

In: Journal of Cardiac Failure, Vol. 9, No. 5, 10.2003, p. 380-383.

Research output: Contribution to journalArticle

@article{b172be4150804c92acd3b376a075bf82,
title = "Dobutamine Potentiates the Peripheral Chemoreflex in Patients With Congestive Heart Failure",
abstract = "Background: β-Adrenergic agonists may increase chemoreflex sensitivity to hypoxia in normal humans. Chemoreflex function is important in the pathophysiology of heart failure. Whether the β-1 agonist dobutamine, which is frequently administered to patients with heart failure, alters their chemoreflex sensitivity is not known. Methods: We tested the hypothesis that dobutamine increases chemoreflex sensitivity in patients with congestive heart failure (CHF) using a randomized, double-blinded, placebo-controlled study design. We assessed the influence of dobutamine on minute ventilation and hemodynamics during normoxic breathing and during peripheral chemoreflex deactivation by hyperoxia (100{\%} O2) in 9 patients with CHF. Results: Dobutamine increased minute ventilation in patients with CHF (9.4 ± 0.9 versus 8.4 ± 0.7 L/min, P = .005) during normoxia. Peripheral chemoreflex deactivation by hyperoxia suppressed the ventilatory effects of dobutamine (10.4 ± 1.4 L/min for dobutamine versus 10.0 ± 1.2 L/min for placebo, P = .34). Conclusions: Dobutamine increases ventilation during normoxia, but not during hyperoxia in patients with CHF. We conclude that dobutamine enhances peripheral chemoreflex sensitivity in patients with congestive heart failure.",
keywords = "Chemoreflex sensitivity, Congestive heart failure, Dobutamine",
author = "Sonia Velez-Roa and {De Borne}, {Philippe Van} and Virend Somers",
year = "2003",
month = "10",
doi = "10.1054/S1071-9164(03)00132-5",
language = "English (US)",
volume = "9",
pages = "380--383",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Dobutamine Potentiates the Peripheral Chemoreflex in Patients With Congestive Heart Failure

AU - Velez-Roa, Sonia

AU - De Borne, Philippe Van

AU - Somers, Virend

PY - 2003/10

Y1 - 2003/10

N2 - Background: β-Adrenergic agonists may increase chemoreflex sensitivity to hypoxia in normal humans. Chemoreflex function is important in the pathophysiology of heart failure. Whether the β-1 agonist dobutamine, which is frequently administered to patients with heart failure, alters their chemoreflex sensitivity is not known. Methods: We tested the hypothesis that dobutamine increases chemoreflex sensitivity in patients with congestive heart failure (CHF) using a randomized, double-blinded, placebo-controlled study design. We assessed the influence of dobutamine on minute ventilation and hemodynamics during normoxic breathing and during peripheral chemoreflex deactivation by hyperoxia (100% O2) in 9 patients with CHF. Results: Dobutamine increased minute ventilation in patients with CHF (9.4 ± 0.9 versus 8.4 ± 0.7 L/min, P = .005) during normoxia. Peripheral chemoreflex deactivation by hyperoxia suppressed the ventilatory effects of dobutamine (10.4 ± 1.4 L/min for dobutamine versus 10.0 ± 1.2 L/min for placebo, P = .34). Conclusions: Dobutamine increases ventilation during normoxia, but not during hyperoxia in patients with CHF. We conclude that dobutamine enhances peripheral chemoreflex sensitivity in patients with congestive heart failure.

AB - Background: β-Adrenergic agonists may increase chemoreflex sensitivity to hypoxia in normal humans. Chemoreflex function is important in the pathophysiology of heart failure. Whether the β-1 agonist dobutamine, which is frequently administered to patients with heart failure, alters their chemoreflex sensitivity is not known. Methods: We tested the hypothesis that dobutamine increases chemoreflex sensitivity in patients with congestive heart failure (CHF) using a randomized, double-blinded, placebo-controlled study design. We assessed the influence of dobutamine on minute ventilation and hemodynamics during normoxic breathing and during peripheral chemoreflex deactivation by hyperoxia (100% O2) in 9 patients with CHF. Results: Dobutamine increased minute ventilation in patients with CHF (9.4 ± 0.9 versus 8.4 ± 0.7 L/min, P = .005) during normoxia. Peripheral chemoreflex deactivation by hyperoxia suppressed the ventilatory effects of dobutamine (10.4 ± 1.4 L/min for dobutamine versus 10.0 ± 1.2 L/min for placebo, P = .34). Conclusions: Dobutamine increases ventilation during normoxia, but not during hyperoxia in patients with CHF. We conclude that dobutamine enhances peripheral chemoreflex sensitivity in patients with congestive heart failure.

KW - Chemoreflex sensitivity

KW - Congestive heart failure

KW - Dobutamine

UR - http://www.scopus.com/inward/record.url?scp=0242268063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242268063&partnerID=8YFLogxK

U2 - 10.1054/S1071-9164(03)00132-5

DO - 10.1054/S1071-9164(03)00132-5

M3 - Article

VL - 9

SP - 380

EP - 383

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 5

ER -